Pulmonary Findings in Hospitalized COVID-19 Patients Assessed by Lung Ultrasonography (LUS) - A Prospective Registry Study

Pulmonary ultrasound in COVID-19 and non-COVID-19 pneumonia in South Africa: An observational study

Background

Pulmonary ultrasound techniques have historically been applied to acute lung diseases to describe lung lesions, particularly in critical care.

Objectives

To explore the role of lung ultrasound (LUS) in hospitalised patients with hypoxaemic pneumonia during the COVID-19 pandemic.

Methods

This was a single-centre prospective, observational study of two groups of adult patients with hypoxaemic pneumonia: those with COVID-19 pneumonia, and those with non-COVID-19 community-acquired pneumonia (CAP). A pulmonologist performed bedside LUS using the Bedside Lung Ultrasound in Emergency (BLUE) protocol, and the findings were verified by an independent study-blinded radiologist.

Results

We enrolled 48 patients with COVID-19 pneumonia and 24 with non-COVID CAP. The COVID-19 patients were significantly older than those with non-COVID CAP (median (interquartile range (IQR)) age 52 (42 - 62.5) years v. 42.5 (36 - 52.5) years, respectively; p=0.007), and had a lower prevalence of HIV infection (25% v. 54%, respectively; p=0.01) and higher prevalences of hypertension (54% v. 7%; p=0.002) and diabetes mellitus (19% v. 8%; p=0.04). In both groups, close to 30% of the patients had severe acute respiratory distress syndrome. A confluent B-line pattern in the right upper lobe was significantly associated with COVID-19 pneumonia compared with the C pattern (relative risk (RR) 3.8; 95% confidence interval (CI) 1.7 - 8.6). Bilateral changes on LUS rather than unilateral or no changes were associated with COVID-19 pneumonia (RR 1.55; 95% CI 1.004 - 2.387). There were no statistically significant differences in median (IQR) lung scores between patients with COVID-19 pneumonia and those with non-COVID CAP (8 (4 - 11.5) v. 7.5 (4.5 - 12.5), respectively). Patients with COVID-19 pneumonia had a higher than predicted mortality. Logistic regression analysis showed a higher Simplified Acute Physiology Score (SAPS II) (RR 1.11; 95% CI 1.02 - 1.21) and a lower total LUS score indicating B lines v. consolidation (RR 0.80; 95% CI 0.65 - 0.99) to be associated with mortality.

Conclusion

Patients with right upper zone consolidation were more likely to have non-COVID CAP than COVID-19 pneumonia. Finding a B pattern as opposed to consolidation was associated with mortality. The admission LUS score was unable to discriminate between COVID-19 and non-COVID CAP, and did not correlate with the ratio of partial pressure of oxygen to fractional inspired oxygen, clinical severity or mortality.

Study synopsis

What the study adds. During the COVID-19 pandemic, in a resource-limited, high-prevalence setting, lung ultrasound (LUS) patterns on admission to hospital were used to distinguish between COVID-19 and other causes in patients with hypoxaemic pneumonia. Patients with right upper zone consolidation were more likely to have non-COVID-19 community-acquired pneumonia (CAP) than COVID-19 pneumonia.Implications of the findings. The admission LUS score was unable to discriminate between COVID-19 pneumonia and non-COVID CAP, and did not correlate with the ratio of partial pressure of oxygen to fractional inspired oxygen, clinical severity or mortality. The pattern was more valuable than the total LUS score in understanding the disease process.

Postmortem Minimally Invasive Autopsy in Critically Ill COVID-19 Patients at the Bedside: A Proof-of-Concept Study at the ICU

BACKGROUND

Economic restrictions and workforce cuts have continually challenged conventional autopsies. Recently, the COVID-19 pandemic has added tissue quality and safety requirements to the investigation of this disease, thereby launching efforts to upgrade autopsy strategies.

METHODS

In this proof-of-concept study, we performed bedside ultrasound-guided minimally invasive autopsy (US-MIA) in the ICU of critically ill COVID-19 patients using a structured protocol to obtain non-autolyzed tissue. Biopsies were assessed for their quality (vitality) and length of biopsy (mm) and for diagnosis. The efficiency of the procedure was monitored in five cases by recording the time of each step and safety issues by swabbing personal protective equipment and devices for viral contamination.

FINDINGS

Ultrasound examination and tissue procurement required a mean time period of 13 min and 54 min, respectively. A total of 318 multiorgan biopsies were obtained from five patients. Quality and vitality standards were fulfilled, which not only allowed for specific histopathological diagnosis but also the reliable detection of SARS-CoV-2 virions in unexpected organs using electronic microscopy and RNA-expressing techniques.

INTERPRETATION

Bedside multidisciplinary US-MIA allows for the fast and efficient acquisition of autolytic-free tissue and offers unappreciated potential to overcome the limitations of research in postmortem studies.

[Interdisciplinary ultrasound-guided, minimally invasive autopsy in COVID-19-deceased patients in the intensive care unit of a university hospital : A proof-of-concept study]

In this feasibility study, we carried out in an interdisciplinary team standardised, ultrasound-guided, minimally invasive autopsy (US-MIA) directly at the bedside of patients who died of COVID-19 in the intensive care unit of the Rechts der Isar Hospital of the Technical University Munich (TUM). The aim of the study was to verify the feasibility, time efficiency and infection hygiene aspects of the process, as well as the quality of the tissue samples. Our results show that bedside US-MIA is suitable for obtaining tissue samples before the onset of postmortem autolysis, and that it can also be carried out quickly and safely. The potential of US-MIA, which has gained little recognition so far, deserves special attention in the context of postmortem diagnosis, research and quality assurance. In the future, these strengths of US-MIA could help to lead postmortem diagnosis into the modern age of pathological deep analytics ("omics").